Cargando…
Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes
Patients on haemodialysis (HD-patients) have an increased risk of premature death. Low levels of IgM antibodies against malondialdehyde (anti-MDA) are associated with increased risk of cardiovascular disease (CVD) with underlying potential mechanisms described. Here, we studied subclasses and isotyp...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141181/ https://www.ncbi.nlm.nih.gov/pubmed/32168733 http://dx.doi.org/10.3390/jcm9030753 |
_version_ | 1783519140141596672 |
---|---|
author | Samal, Shailesh Kumar Qureshi, Abdul Rashid Rahman, Mizanur Stenvinkel, Peter Frostegård, Johan |
author_facet | Samal, Shailesh Kumar Qureshi, Abdul Rashid Rahman, Mizanur Stenvinkel, Peter Frostegård, Johan |
author_sort | Samal, Shailesh Kumar |
collection | PubMed |
description | Patients on haemodialysis (HD-patients) have an increased risk of premature death. Low levels of IgM antibodies against malondialdehyde (anti-MDA) are associated with increased risk of cardiovascular disease (CVD) with underlying potential mechanisms described. Here, we studied subclasses and isotypes of anti-MDA in 210 HD-patients with mortality as outcome (56% men, median age 66, Interquartile range (IQR) 51–74 years, vintage time 29 (15–58) months, mean follow up period of 41 (20–60)months). Patients were also divided into inflamed c-reactive protein (CRP >5.6 mg/mL) and non-inflamed. Antibody levels were measured by ELISA. In multivariate risk analysis, patients in low tertile of IgM anti-MDA sub-distribution hazard ratio (sHR 0.54); 95% confidence interval (CI: 0.34–0.89) inversely and significantly associated with all-cause mortality after five years, after adjusting for confounders. Low tertile of IgG (sHR 0.48, 95%CI: 0.25–0.90, p = 0.02) and IgG1 (sHR 0.50, CI: 0.24–1.04, p = 0.06) was associated low mortality among non-inflamed patients. In contrast, anti-MDA IgG2 among inflamed patients was significantly associated with increased mortality, IgG2(sHR 2.33, CI: 1.16–4.68, p = 0.01). IgM anti-MDA was a novel biomarker among HD-patients with low levels being associated with mortality, while low levels of IgG and IgG1 but not IgA anti-MDA were associated with mortality only among non-inflamed patients. IgG2 anti-MDA was a significant risk marker among inflamed patients, which could be related to infection. |
format | Online Article Text |
id | pubmed-7141181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71411812020-04-10 Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes Samal, Shailesh Kumar Qureshi, Abdul Rashid Rahman, Mizanur Stenvinkel, Peter Frostegård, Johan J Clin Med Article Patients on haemodialysis (HD-patients) have an increased risk of premature death. Low levels of IgM antibodies against malondialdehyde (anti-MDA) are associated with increased risk of cardiovascular disease (CVD) with underlying potential mechanisms described. Here, we studied subclasses and isotypes of anti-MDA in 210 HD-patients with mortality as outcome (56% men, median age 66, Interquartile range (IQR) 51–74 years, vintage time 29 (15–58) months, mean follow up period of 41 (20–60)months). Patients were also divided into inflamed c-reactive protein (CRP >5.6 mg/mL) and non-inflamed. Antibody levels were measured by ELISA. In multivariate risk analysis, patients in low tertile of IgM anti-MDA sub-distribution hazard ratio (sHR 0.54); 95% confidence interval (CI: 0.34–0.89) inversely and significantly associated with all-cause mortality after five years, after adjusting for confounders. Low tertile of IgG (sHR 0.48, 95%CI: 0.25–0.90, p = 0.02) and IgG1 (sHR 0.50, CI: 0.24–1.04, p = 0.06) was associated low mortality among non-inflamed patients. In contrast, anti-MDA IgG2 among inflamed patients was significantly associated with increased mortality, IgG2(sHR 2.33, CI: 1.16–4.68, p = 0.01). IgM anti-MDA was a novel biomarker among HD-patients with low levels being associated with mortality, while low levels of IgG and IgG1 but not IgA anti-MDA were associated with mortality only among non-inflamed patients. IgG2 anti-MDA was a significant risk marker among inflamed patients, which could be related to infection. MDPI 2020-03-11 /pmc/articles/PMC7141181/ /pubmed/32168733 http://dx.doi.org/10.3390/jcm9030753 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Samal, Shailesh Kumar Qureshi, Abdul Rashid Rahman, Mizanur Stenvinkel, Peter Frostegård, Johan Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes |
title | Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes |
title_full | Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes |
title_fullStr | Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes |
title_full_unstemmed | Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes |
title_short | Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes |
title_sort | antibodies against malondialdehyde in haemodialysis patients and its association with clinical outcomes: differences between subclasses and isotypes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141181/ https://www.ncbi.nlm.nih.gov/pubmed/32168733 http://dx.doi.org/10.3390/jcm9030753 |
work_keys_str_mv | AT samalshaileshkumar antibodiesagainstmalondialdehydeinhaemodialysispatientsanditsassociationwithclinicaloutcomesdifferencesbetweensubclassesandisotypes AT qureshiabdulrashid antibodiesagainstmalondialdehydeinhaemodialysispatientsanditsassociationwithclinicaloutcomesdifferencesbetweensubclassesandisotypes AT rahmanmizanur antibodiesagainstmalondialdehydeinhaemodialysispatientsanditsassociationwithclinicaloutcomesdifferencesbetweensubclassesandisotypes AT stenvinkelpeter antibodiesagainstmalondialdehydeinhaemodialysispatientsanditsassociationwithclinicaloutcomesdifferencesbetweensubclassesandisotypes AT frostegardjohan antibodiesagainstmalondialdehydeinhaemodialysispatientsanditsassociationwithclinicaloutcomesdifferencesbetweensubclassesandisotypes |